日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Dacomitinib as a First-Line Therapy for Advanced EGFR-Mutated Non-Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study

达克替尼作为一线疗法治疗无脑转移的晚期EGFR突变非小细胞肺癌：一项多中心回顾性观察研究

期刊:Cancer Medicine
影响因子:3.1
doi:10.1002/cam4.71659
Hsu, Ping-Chih; Ko, How-Wen; Chiu, Li-Chung; Huang, Shih-Hao; Lee, Chung-Shu; Lin, Yu-Ching; Kuo, Scott Chih-Hsi; Ju, Jia-Shiuan; Wang, Chin-Chou; Yang, Cheng-Ta
肺癌
肿瘤
肿瘤免疫
EGF
神经科学
EGFR
细胞生物学
发表日期：2026
文献求助 收藏

Plasma phenylalanine is associated with hospital mortality in acute respiratory distress syndrome: a prospective metabolic profiling cohort study

血浆苯丙氨酸与急性呼吸窘迫综合征患者的院内死亡率相关：一项前瞻性代谢谱队列研究

期刊:European Journal of Medical Research
影响因子:3.4
doi:10.1186/s40001-025-03043-y
Chiu, Li-Chung; Lo, Chi-Jen; Fan, Chun-Ming; Tang, Hsiang-Yu; Chan, Tien-Ming; Ko, How-Wen; Kuo, Scott Chih-Hsi; Hsu, Ping-Chih; Lee, Chung-Shu; Lin, Yu-Jr; Kao, Kuo-Chin; Chuang, Li-Pang; Hu, Han-Chung; Cheng, Mei-Ling
代谢
发表日期：2025
文献求助 收藏

Clinical outcome analysis of different first‑ and second‑generation EGFR‑tyrosine kinase inhibitors in untreated patients with EGFR‑mutated non‑small cell lung cancer with baseline brain metastasis.

对未经治疗的 EGFR 突变非小细胞肺癌伴基线脑转移患者进行不同的第一代和第二代 EGFR 酪氨酸激酶抑制剂的临床结果分析

期刊:Oncology Letters
影响因子:2.2
doi:10.3892/ol.2025.14947
Hsu Chen-Chuan, Chiu Li-Chung, Ko How-Wen, Wu Chiao-En, Kuo Scott Chih-Hsi, Ju Jia-Shiuan, Huang Allen Chung-Cheng, Wang Chin-Chou, Yang Cheng-Ta, Hsu Ping-Chih
细胞生物学
肺癌
EGFR
肿瘤免疫
发表日期：2025
文献求助 收藏

Urinary cadmium concentration is associated with the severity and clinical outcomes of COVID-19: a bicenter observational cohort study

尿镉浓度与 COVID-19 的严重程度和临床结局相关：一项双中心观察性队列研究

期刊:Environmental Health
影响因子:5.9
doi:10.1186/s12940-024-01070-6
Chiu, Li-Chung; Lee, Chung-Shu; Hsu, Ping-Chih; Li, Hsin-Hsien; Chan, Tien-Ming; Hsiao, Ching-Chung; Kuo, Scott Chih-Hsi; Ko, How-Wen; Lin, Shu-Min; Wang, Chun-Hua; Lin, Horng-Chyuan; Chu, Pao-Hsien; Yen, Tzung-Hai
发表日期：2024
文献求助 收藏

A Clinical Analysis of Anti-Programmed Death-Ligand 1 (PD-L1) Immune Checkpoint Inhibitor Treatments Combined with Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer

抗程序性死亡配体1 (PD-L1) 免疫检查点抑制剂联合化疗治疗未经治疗的广泛期小细胞肺癌的临床分析

期刊:Vaccines
影响因子:3.4
doi:10.3390/vaccines12050474
Hsu, Ping-Chih; Wu, Bing-Chen; Wang, Chin-Chou; Chiu, Li-Chung; Chang, Chiung-Hsin; Liu, Ping-Chi; Wu, Chiao-En; Kuo, Scott Chih-Hsi; Ju, Jia-Shiuan; Huang, Allen Chung-Cheng; Lin, Yu-Ching; Yang, Cheng-Ta; Ko, How-Wen
Checkpoint
肺癌
肿瘤
肿瘤免疫
PD-L1
细胞生物学
免疫/内分泌
发表日期：2024
文献求助 收藏

Factors associated with prolonged progression-free survival of patients treated with first-line afatinib for advanced epidermal growth factor receptor-mutated non-small cell lung cancer

一线阿法替尼治疗晚期表皮生长因子受体突变型非小细胞肺癌患者延长无进展生存期的相关因素

期刊:Thoracic Cancer
影响因子:2.3
doi:10.1111/1759-7714.15212
Chiu, Li-Chung; Hsu, Ping-Chih; Wang, Chin-Chou; Ko, How-Wen; Kuo, Scott Chih-Hsi; Ju, Jia-Shiuan; Tung, Pi-Hung; Huang, Allen Chung-Cheng; Yang, Cheng-Ta
肺癌
肿瘤
肿瘤免疫
信号转导
细胞生物学
发表日期：2024
文献求助 收藏

Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan

阿法替尼治疗未经治疗的伴有主要罕见表皮生长因子受体 (EGFR) 突变 (G719X/L861Q/S768I) 的 IIIB/IV 期肺腺癌：一项台湾多中心观察性研究

期刊:Targeted Oncology
影响因子:4
doi:10.1007/s11523-023-00946-w
Hsu, Ping-Chih; Lee, Suey-Haur; Chiu, Li-Chung; Lee, Chung-Shu; Wu, Chiao-En; Kuo, Scott Chih-Hsi; Ju, Jia-Shiuan; Huang, Allen Chung-Cheng; Li, Shih-Hong; Ko, Ho-Wen; Yang, Cheng-Ta; Wang, Chin-Chou
肿瘤
肿瘤免疫
信号转导
EGF
EGFR
发表日期：2023
文献求助 收藏

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors

对于接受一线贝伐珠单抗联合第一/二代EGFR酪氨酸激酶抑制剂治疗的晚期表皮生长因子受体突变肺腺癌患者，序贯治疗方案

期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2023.1249106
Hsu, Ping-Chih; Huang, Chun-Yao; Lin, Yu-Ching; Lee, Suey-Haur; Chiu, Li-Chung; Wu, Chiao-En; Kuo, Scott Chih-Hsi; Ju, Jia-Shiuan; Huang, Allen Chung-Cheng; Ko, Ho-Wen; Wang, Chin-Chou; Yang, Cheng-Ta
肿瘤
肿瘤免疫
信号转导
EGF
EGFR
发表日期：2023
文献求助 收藏

Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study

比较阿法替尼和厄洛替尼联合贝伐单抗治疗未经治疗的IIIB/IV期表皮生长因子受体突变型肺腺癌患者的疗效：一项多中心临床分析研究

期刊:Therapeutic Advances in Medical Oncology
影响因子:4.2
doi:10.1177/17588359221113278
Lee, Suey-Haur; Lin, Yu-Ching; Chiu, Li-Chung; Ju, Jia-Shiuan; Tung, Pi-Hung; Huang, Allen Chung-Cheng; Li, Shih-Hong; Fang, Yueh-Fu; Chen, Chih-Hung; Kuo, Scott Chih-Hsi; Wang, Chin-Chou; Yang, Cheng-Ta; Hsu, Ping-Chih
信号转导
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

Immunotherapy and Vaccination in Surgically Resectable Non-Small Cell Lung Cancer (NSCLC)

手术切除的非小细胞肺癌（NSCLC）的免疫疗法和疫苗接种

期刊:Vaccines
影响因子:3.4
doi:10.3390/vaccines9070689
Chiu, Li-Chung; Lin, Shu-Min; Lo, Yu-Lun; Kuo, Scott Chih-Hsi; Yang, Cheng-Ta; Hsu, Ping-Chih
肺癌
肿瘤
肿瘤免疫
CLC
细胞生物学
免疫/内分泌
发表日期：2021
文献求助 收藏